Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-21

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases

NCT02127450

Enterobacteria Non Susceptible to Carbapenem Carrier Enterobacteria Susceptible to Carbapenem Carrier

COMPLETED

Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments

NCT01703299

Carbapenem-induced Resistance

COMPLETED

Infections With Enterobacteria Producing Carbapenemases at the University Hospitals of Strasbourg

NCT04995965

Nfections, Enterobacterial

UNKNOWN

Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae on Admission to a French University Teaching Hospital

NCT05798351

Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae

RECRUITING

Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region

NCT02803710

Infection With Beta-lactam Resistance in Enterobacteriaceae

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type VIM.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carbapenemase-Producing Enterobacteriaceae

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥18)
* Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022
* Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.